Group 1 - The core point of the article is that Baiyang Pharmaceutical announced the convening of its fourth board meeting to discuss a proposal regarding capital increase and related transactions with its wholly-owned subsidiary [1] - For the year 2024, Baiyang Pharmaceutical's revenue composition is as follows: sales of pharmaceuticals and medical devices account for 92.5%, brand services account for 7.18%, and other businesses account for 0.32% [1] - As of the time of reporting, Baiyang Pharmaceutical has a market capitalization of 11.9 billion yuan [1]

Group 1 - The core viewpoint of the article is that Baiyang Pharmaceutical held its fourth board meeting on September 17, 2025, to discuss the appointment of a securities affairs representative and other related documents [1] - For the fiscal year 2024, Baiyang Pharmaceutical's revenue composition is as follows: 92.5% from sales of pharmaceuticals and medical devices, 7.18% from brand services, and 0.32% from other businesses [1] - As of the time of reporting, Baiyang Pharmaceutical has a market capitalization of 15.9 billion yuan [1]

Group 1 - The core revenue composition of Baiyang Pharmaceutical for the year 2024 is as follows: sales of pharmaceuticals and medical devices account for 92.5%, brand services account for 7.18%, and other businesses account for 0.32% [1] Group 2 - As of the announcement date, Baiyang Pharmaceutical Group has pledged approximately 146 million shares, representing 39.49% of its total holdings [3] - Beijing Baiyang Chengchuang Pharmaceutical Investment Co., Ltd. has pledged 9.98 million shares, which is 49.9% of its holdings [3] - Tianjin Huitong Asset Management Partnership has pledged 2.8 million shares, accounting for 48.86% of its holdings [3] - Tianjin Haohui Asset Management Partnership has pledged 2.1 million shares, representing 48.36% of its holdings [3] - Tianjin Huizhong Asset Management Partnership has pledged 2.1 million shares, which is 48.79% of its holdings [3] - Tianjin Huitong Asset Management Partnership has pledged 1.6 million shares, accounting for 48.93% of its holdings [3]